Tumor grade and molecular subtypes on local control in breast cancer radiotherapy: Does fractionation really matter? A retrospective control study group

Darby, 2011, Effect of radiotherapy after breast –conserving surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 10,801 women in 17 randomized trials, Lancet, 378, 1707, 10.1016/S0140-6736(11)61629-2 McGale, 2014, Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomized trials, Lancet, 383, 2027 Bartelinik, 2007, Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial, J Clin Oncol, 25, 3259, 10.1200/JCO.2007.11.4991 Budach, 2015, Hypofractionated radiotherapy as adjuvant treatment in early breast cancer. A review and meta-analysis of randomized controlled trials, Breast Care, 10, 240, 10.1159/000439007 Hasan, 2017, Utilization trend and regimens of hypofractionated whole breast radiation therapy in the United States, Breast Cancer Res, 162, 317, 10.1007/s10549-017-4120-0 Whelan, 2010, Long-term results of hypofractionated radiation therapy for breast cancer, N Engl J Med, 362, 513, 10.1056/NEJMoa0906260 Bane, 2014, Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy, Ann Oncol, 25, 992, 10.1093/annonc/mdu090 Smith, 2018, Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline, Pract Radiat Oncol, 8, 145, 10.1016/j.prro.2018.01.012 Lazzari, 2017, Predictive parameters in hypofractionated whole-breast 3D conformal radiotherapy according to the Ontario Canadian Trial, OncoTargets Therapy, 10, 1835, 10.2147/OTT.S127833 Cheang, 2004, Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype, Clin Cancer Res, 10, 5367 Voduc, 2010, Breast Cancer subtypes and the risk of local and regional relapse, J Clin Oncol, 28, 1684, 10.1200/JCO.2009.24.9284 Haviland, 2013, The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials, Lancet Oncol, 1086, 10.1016/S1470-2045(13)70386-3 Herbert, 2012, The impact of hypofractionated whole breast radiotherapy on local relapse in Ptient with Grade 3 early breast cancer: a population – based cohort study, Int J Radiat Oncol Biol Phys, 82, 2086, 10.1016/j.ijrobp.2011.01.055 Smith, 2011, Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline, Int J Radiat Oncol Biol Phys, 81, 59, 10.1016/j.ijrobp.2010.04.042 Jones, 2009, Impact of pathological characteristics on local relapse after breast –conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial, J Clin Oncol, 27, 4939, 10.1200/JCO.2008.21.5764 Bloom, 1957, Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years, Br J Cancer, 11, 359, 10.1038/bjc.1957.43 Douglas, 1982, Superfractionation: its rationale and anticipate benefits, Int J Radiat Oncol Biol Phys, 8, 1143, 10.1016/0360-3016(82)90062-1 Brenner, 2002, Direct evidence that prostate tumors show high sensivity to fractionation (low alpha/beta ratio), similar to late- responding normal tissue, Int J Radiat Oncol Biol Phys, 52, 6, 10.1016/S0360-3016(01)02664-5 Arcangeli, 2010, A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer, Int J Radiat Oncol Biol Phys, 78, 11, 10.1016/j.ijrobp.2009.07.1691 Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093 Park, 2012, Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using himmunohistochemistry, Breast, 21, 50, 10.1016/j.breast.2011.07.008 Kyndi, 2008, Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group, J Clin Oncol, 26, 1419, 10.1200/JCO.2007.14.5565 Nguyen, 2008, Breast Cancer subtype approximated by Estrogen receptor, Progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy, J Clin Oncol, 26, 2373, 10.1200/JCO.2007.14.4287 Pietras, 1999, Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells over-expressing this oncogene, Cancer Res, 59, 1347 Duru, 2012, HER2–associated radioresistance of breast cancer stem cells isolated from HER-2 negative breast cancer cells, Clin Cancer Res, 18, 6634, 10.1158/1078-0432.CCR-12-1436 Kim, 2016, STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers, Oncotarget, 7, 7055, 10.18632/oncotarget.6855 Hou, 2016, HER2 reduces breast cancer radiosensivityby activating focal adhesion Kinase in vivo and in vitro, Oncotarget, 7, 45186, 10.18632/oncotarget.9870 Horton, 2015, FAS death receptor: a breast cancer subtype-specific radiation response biomarker and potential therapeutic target, Radiat Res, 184, 456, 10.1667/RR14089.1 Chen, 2017, Estrogen receptor mediates the radiosensivity of Triple-Negative Breast Cancer cells, Med Sci Monit, 23, 2674, 10.12659/MSM.904810